Ticagrelor vs clopidogrel when coadministered with bivalirudin in patients with acute coronary syndrome undergoing percutaneous coronary intervention
CONCLUSION: As an initial treatment strategy, bivalirudin plus ticagrelor could reduce the 12-month risk of ischemic events compared with bivalirudin plus clopidogrel significantly without increasing the bleeding risk in ACS patients undergoing PCI.PMID:38623472 | PMC:PMC11017352 | DOI:10.1016/j.rpth.2024.102375
Source: Thrombosis and Haemostasis - Category: Hematology Authors: Yang Li Yi Li Miaohan Qiu Yu Xue Kai Xu Yaling Han Source Type: research
More News: Academia | Angiomax | Angioplasty | Bleeding | Clopidogrel | Coronary Angioplasty | Heart Attack | Hematology | Ischemic Stroke | Percutaneous Coronary Intervention | Plavix | Stroke | Study | Thrombosis